Allogene Therapeutics ALLO Common stock, capital shares reserved for future issuance
Common stock, capital shares reserved for future issuance at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockCapitalSharesReservedForFutureIssuance.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's common stock, capital shares reserved for future issuance.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's common stock, capital shares reserved for future issuance?
- Allogene Therapeutics (ALLO) reported common stock, capital shares reserved for future issuance of $8.96M in Q1 2026.
- How has Allogene Therapeutics's common stock, capital shares reserved for future issuance changed year-over-year?
- Allogene Therapeutics's common stock, capital shares reserved for future issuance increased by 72.5% year-over-year, from $5.2M to $8.96M.